{"id":"https://openalex.org/W2133377772","doi":"https://doi.org/10.1111/j.1753-0407.2010.00082.x","title":"Pioglitazone and the risk of cardiovascular events in patients with Type 2 diabetes receiving concomitant treatment with nitrates, renin\u2013angiotensin system blockers, or insulin: results from the PROactive study (PROactive 20)","display_name":"Pioglitazone and the risk of cardiovascular events in patients with Type 2 diabetes receiving concomitant treatment with nitrates, renin\u2013angiotensin system blockers, or insulin: results from the PROactive study (PROactive 20)","alternate_titles":[],"publication_year":2010,"publication_date":"2010-08-16","ids":{"openalex":"https://openalex.org/W2133377772","doi":"https://doi.org/10.1111/j.1753-0407.2010.00082.x","mag":"2133377772","pmid":"https://pubmed.ncbi.nlm.nih.gov/20923486"},"language":"en","primary_location":{"id":"doi:10.1111/j.1753-0407.2010.00082.x","doi":"https://doi.org/10.1111/j.1753-0407.2010.00082.x","is_oa":false,"landing_page_url":"https://doi.org/10.1111/j.1753-0407.2010.00082.x","pdf_url":null,"source":{"id":"https://openalex.org/S181994529","display_name":"Journal of Diabetes","issn_l":"1753-0407","issn":["1753-0407","1753-0393"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-100","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Diabetes","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2133377772"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5028685517","display_name":"Erland Erdmann","orcid":"https://orcid.org/0000-0002-9887-3736","observed_orcids":["https://orcid.org/0000-0002-9887-3736"]},"institutions":[{"id":"https://openalex.org/I180923762","display_name":"University of Cologne","ror":"https://ror.org/00rcxh774","country_code":"DE","type":"education","lineage":["https://openalex.org/I180923762"]},{"id":"https://openalex.org/I4210153755","display_name":"University Hospital Cologne","ror":"https://ror.org/05mxhda18","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I4210153755"]}],"countries":["DE"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Erland ERDMANN","raw_affiliation_strings":["Medizinische Klinik III der Universit\u00e4t zu K\u00f6ln, K\u00f6ln, Germany. erland.erdmann@uni-koeln.de","Medizinische Klinik III der Universit\u00e4t zu K\u00f6ln, K\u00f6ln, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medizinische Klinik III der Universit\u00e4t zu K\u00f6ln, K\u00f6ln, Germany. erland.erdmann@uni-koeln.de","institution_ids":["https://openalex.org/I180923762"]},{"raw_affiliation_string":"Medizinische Klinik III der Universit\u00e4t zu K\u00f6ln, K\u00f6ln, Germany","institution_ids":["https://openalex.org/I180923762","https://openalex.org/I4210153755"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003459581","display_name":"Robert G. Spanheimer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210140176","display_name":"Takeda (United States)","ror":"https://ror.org/03bygaq51","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140176","https://openalex.org/I44892455"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Robert SPANHEIMER","raw_affiliation_strings":["Takeda Pharmaceuticals North America, Deerfield, Illinois, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Takeda Pharmaceuticals North America, Deerfield, Illinois, USA","institution_ids":["https://openalex.org/I4210140176"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025169113","display_name":"Bernard H. Charbonnel","orcid":"https://orcid.org/0000-0002-2117-9279","observed_orcids":["https://orcid.org/0000-0002-2117-9279"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Bernard CHARBONNEL","raw_affiliation_strings":["Clinique d\u2019Endocrinologie, Ho\u0302tel Dieu, Nantes Cedex 1, France","Clinique d\u2019Endocrinologie, H\u00f4tel Dieu, Nantes Cedex 1, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinique d\u2019Endocrinologie, Ho\u0302tel Dieu, Nantes Cedex 1, France","institution_ids":[]},{"raw_affiliation_string":"Clinique d\u2019Endocrinologie, H\u00f4tel Dieu, Nantes Cedex 1, France","institution_ids":[]}]},{"author_position":"last","author":{"id":null,"display_name":"on behalf of the PROactive Study Investigators","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"on behalf of the PROactive Study Investigators","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5028685517"],"corresponding_institution_ids":["https://openalex.org/I180923762","https://openalex.org/I4210153755"],"apc_list":{"value":3000,"currency":"USD","value_usd":3000},"apc_paid":null,"fwci":3.5339,"has_fulltext":false,"cited_by_count":49,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.92790229,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":86,"max":99},"biblio":{"volume":"2","issue":"3","first_page":"212","last_page":"220"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9940999746322632,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9940999746322632,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10027","display_name":"Diabetes, Cardiovascular Risks, and Lipoproteins","score":0.0032999999821186066,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10198","display_name":"Heart Failure Treatment and Management","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pioglitazone","display_name":"pioglitazone","score":1.0},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.972000002861023},{"id":"https://openalex.org/keywords/cardiovascular-events","display_name":"cardiovascular events","score":0.7110000252723694},{"id":"https://openalex.org/keywords/nitrate","display_name":"nitrate","score":0.8360000252723694},{"id":"https://openalex.org/keywords/renin-angiotensin-system-inhibitors","display_name":"renin-angiotensin system inhibitors","score":0.9980000257492065},{"id":"https://openalex.org/keywords/insulin","display_name":"insulin","score":0.9350000023841858},{"id":"https://openalex.org/keywords/rosiglitazone","display_name":"rosiglitazone","score":0.8080000281333923},{"id":"https://openalex.org/keywords/myocardial-infarction","display_name":"myocardial infarction","score":0.8870000243186951},{"id":"https://openalex.org/keywords/stroke","display_name":"stroke","score":0.9819999933242798},{"id":"https://openalex.org/keywords/all-cause-mortality","display_name":"all-cause mortality","score":0.9660000205039978},{"id":"https://openalex.org/keywords/edema","display_name":"edema","score":0.7129999995231628},{"id":"https://openalex.org/keywords/heart-failure","display_name":"heart failure","score":0.9929999709129333},{"id":"https://openalex.org/keywords/drug-interactions","display_name":"drug interactions","score":0.5059999823570251},{"id":"https://openalex.org/keywords/proactive-trial","display_name":"PROactive trial","score":0.7289999723434448}],"concepts":[{"id":"https://openalex.org/C2778384471","wikidata":"https://www.wikidata.org/wiki/Q417765","display_name":"Pioglitazone","level":4,"score":0.9528812170028687},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.912439227104187},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6824795007705688},{"id":"https://openalex.org/C2778198053","wikidata":"https://www.wikidata.org/wiki/Q181754","display_name":"Heart failure","level":2,"score":0.6046168804168701},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.5716348886489868},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.5409875512123108},{"id":"https://openalex.org/C164705383","wikidata":"https://www.wikidata.org/wiki/Q10379","display_name":"Cardiology","level":1,"score":0.5177428126335144},{"id":"https://openalex.org/C207103383","wikidata":"https://www.wikidata.org/wiki/Q3930246","display_name":"Hazard ratio","level":3,"score":0.5172529816627502},{"id":"https://openalex.org/C2780645631","wikidata":"https://www.wikidata.org/wiki/Q671554","display_name":"Stroke (engine)","level":2,"score":0.49679115414619446},{"id":"https://openalex.org/C500558357","wikidata":"https://www.wikidata.org/wiki/Q12152","display_name":"Myocardial infarction","level":2,"score":0.48963838815689087},{"id":"https://openalex.org/C2778848681","wikidata":"https://www.wikidata.org/wiki/Q6725716","display_name":"Macrovascular disease","level":4,"score":0.48683303594589233},{"id":"https://openalex.org/C2780152017","wikidata":"https://www.wikidata.org/wiki/Q424771","display_name":"Rosiglitazone","level":3,"score":0.45685604214668274},{"id":"https://openalex.org/C2779306644","wikidata":"https://www.wikidata.org/wiki/Q2002370","display_name":"Insulin","level":2,"score":0.45428183674812317},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.43129763007164},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.425589382648468},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.28603485226631165},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.2174854874610901},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.06237608194351196},{"id":"https://openalex.org/C78519656","wikidata":"https://www.wikidata.org/wiki/Q101333","display_name":"Mechanical engineering","level":1,"score":0.0},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C127413603","wikidata":"https://www.wikidata.org/wiki/Q11023","display_name":"Engineering","level":0,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000077205","descriptor_name":"Pioglitazone","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000806","descriptor_name":"Angiotensin-Converting Enzyme Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000806","descriptor_name":"Angiotensin-Converting Enzyme Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000150","qualifier_name":"complications","is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D003925","descriptor_name":"Diabetic Angiopathies","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D003925","descriptor_name":"Diabetic Angiopathies","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D003925","descriptor_name":"Diabetic Angiopathies","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":true},{"descriptor_ui":"D004487","descriptor_name":"Edema","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D004487","descriptor_name":"Edema","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006333","descriptor_name":"Heart Failure","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D006333","descriptor_name":"Heart Failure","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D007328","descriptor_name":"Insulin","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D007328","descriptor_name":"Insulin","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009566","descriptor_name":"Nitrates","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D009566","descriptor_name":"Nitrates","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D015337","descriptor_name":"Multicenter Studies as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017202","descriptor_name":"Myocardial Ischemia","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":true},{"descriptor_ui":"D017202","descriptor_name":"Myocardial Ischemia","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D017668","descriptor_name":"Age of Onset","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D045162","descriptor_name":"Thiazolidinediones","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D045162","descriptor_name":"Thiazolidinediones","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1111/j.1753-0407.2010.00082.x","doi":"https://doi.org/10.1111/j.1753-0407.2010.00082.x","is_oa":false,"landing_page_url":"https://doi.org/10.1111/j.1753-0407.2010.00082.x","pdf_url":null,"source":{"id":"https://openalex.org/S181994529","display_name":"Journal of Diabetes","issn_l":"1753-0407","issn":["1753-0407","1753-0393"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-100","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Diabetes","raw_type":"journal-article"},{"id":"pmid:20923486","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/20923486","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of diabetes","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":36,"referenced_works":["https://openalex.org/W71678318","https://openalex.org/W157267557","https://openalex.org/W175506309","https://openalex.org/W1522960617","https://openalex.org/W1523312932","https://openalex.org/W1527881916","https://openalex.org/W1966255583","https://openalex.org/W1968330079","https://openalex.org/W1969533014","https://openalex.org/W1972285818","https://openalex.org/W1982311681","https://openalex.org/W2006837571","https://openalex.org/W2015932894","https://openalex.org/W2024874163","https://openalex.org/W2028596300","https://openalex.org/W2040274922","https://openalex.org/W2050445438","https://openalex.org/W2075183867","https://openalex.org/W2075365670","https://openalex.org/W2078447913","https://openalex.org/W2081276121","https://openalex.org/W2094662494","https://openalex.org/W2105407506","https://openalex.org/W2105719905","https://openalex.org/W2112618213","https://openalex.org/W2114978217","https://openalex.org/W2127125241","https://openalex.org/W2131490500","https://openalex.org/W2135729475","https://openalex.org/W2142271188","https://openalex.org/W2149460582","https://openalex.org/W2154067841","https://openalex.org/W2159969745","https://openalex.org/W2164160382","https://openalex.org/W3109617681","https://openalex.org/W4241471955"],"related_works":["https://openalex.org/W2397658445","https://openalex.org/W2410299301","https://openalex.org/W316926694","https://openalex.org/W2110102664","https://openalex.org/W1982820415","https://openalex.org/W1561779083","https://openalex.org/W2120310114","https://openalex.org/W1984773197","https://openalex.org/W2159969745","https://openalex.org/W2171941596"],"abstract_inverted_index":{"BACKGROUND:":[0],"Patients":[1,86],"with":[2,11,39,60,81,164,223,242],"Type":[3],"2":[4],"diabetes":[5],"mellitus":[6],"(T2DM)":[7],"are":[8],"often":[9],"treated":[10],"multiple":[12],"glucose-lowering":[13,96],"and":[14,75,83,97,115,124,145,191,198,244,249],"cardiovascular":[15,76,98],"agents.":[16],"The":[17,41,63,100,139,193],"concomitant":[18],"use":[19,157],"of":[20,51,102,122,141,154,158,196,220,247],"nitrates,":[21,131,159,228],"renin-angiotensin":[22],"system":[23],"(RAS)":[24],"blockers,":[25,133,161,230],"or":[26,89,134,162,231],"insulin":[27,135],"has":[28],"been":[29],"linked":[30],"to":[31,47,93,170],"a":[32,67],"potential":[33,56],"increase":[34],"in":[35,78,91,128,225],"myocardial":[36,112],"ischemic":[37],"risk":[38,140,195,219],"rosiglitazone.":[40],"PROactive":[42,64],"database":[43],"provides":[44],"an":[45,217],"opportunity":[46],"investigate":[48],"the":[49,55,155,177,205,237],"effects":[50],"these":[52],"medications":[53],"on":[54,104],"macrovascular":[57,84,221],"benefits":[58],"reported":[59],"pioglitazone.":[61],"METHODS:":[62],"study":[65],"was":[66,107,151,202],"randomized":[68],"double-blind":[69],"prospective":[70],"trial":[71],"that":[72],"evaluated":[73],"mortality":[74],"morbidity":[77],"5238":[79],"patients":[80,226,235],"T2DM":[82],"disease.":[85],"received":[87],"pioglitazone":[88,103,148,224],"placebo":[90,150],"addition":[92],"their":[94],"baseline":[95,156,188,206],"medications.":[99],"effect":[101],"composite":[105,179],"endpoints":[106,180],"evaluated,":[108],"including":[109],"all-cause":[110,142],"death,":[111,143],"infarction":[113],"(MI),":[114],"stroke,":[116],"as":[117,119],"well":[118],"safety":[120],"events":[121,222,246],"edema":[123,197,248],"serious":[125,199],"heart":[126,200,250],"failure,":[127],"subgroups":[129,190],"using":[130],"RAS":[132,160,229],"at":[136],"baseline.":[137],"RESULTS:":[138],"MI,":[144],"stroke":[146],"for":[147,176],"versus":[149],"similar":[152],"regardless":[153],"insulin,":[163],"hazard":[165],"ratios":[166],"ranging":[167],"from":[168],"0.81":[169],"0.87.":[171],"Similar":[172],"results":[173],"were":[174,183,252],"obtained":[175],"other":[178],"analyzed.":[181],"There":[182],"no":[184],"significant":[185],"interactions":[186],"between":[187],"medication":[189,207],"treatment.":[192],"increased":[194,218],"failure":[201,251],"consistent":[203],"across":[204],"subgroups.":[208],"CONCLUSIONS:":[209],"This":[210],"post":[211],"hoc":[212],"analysis":[213],"did":[214],"not":[215],"reveal":[216],"receiving":[227],"insulin.":[232],"Rather,":[233],"all":[234],"realized":[236],"same":[238],"trend":[239],"towards":[240],"benefit":[241],"pioglitazone,":[243],"adverse":[245],"predictable.":[253]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2133377772","counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":3},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":4},{"year":2016,"cited_by_count":3},{"year":2015,"cited_by_count":6},{"year":2014,"cited_by_count":5},{"year":2013,"cited_by_count":3},{"year":2012,"cited_by_count":8}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2016-06-24T00:00:00"}
